Hereditary Gastrointestinal Cancer Registry banner

Research Studies

Laboratory research that studies blood and tissue with and without cancer helps scientists understand how cancer develops. This knowledge opens possibilities for new approaches to treating and preventing cancers. Clinical trials test these new approaches under strict safety controls to help doctors discover the best treatments possible.

With participants’ permission, the Registry can refer eligible participants to these and other research studies. To learn more about these and other studies, please contact the Registry staff at 1-877-422-6860 or registry.coordinator@hci.utah.edu.

A Double-Blind, Randomized, Phase III Trial of The Safety and Efficacy of CPP-1X/Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP)
Please see clinicaltrials.gov for more information.

Pilot Study of Sulindac/EGFR-Inhibitor in AFAP Patients with Duodenal Polyps
This clinical trial investigates whether the combination of two drugs, erlotinib and sulindac, is safe and effective in reducing polyp size and development in people who have duodenal and colorectal polyps due to familial adenomatous polyposis (FAP) or attenuated familial adenomatous polyposis (AFAP).